Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 34Uterine Cervical Neoplasms 24Fallopian Tube Neoplasms 18Endometrial Neoplasms 16Neoplasm Metastasis 10Lung Neoplasms 9Pancreatic Neoplasms 8Stomach Neoplasms 7Colorectal Neoplasms 7Carcinoma, Transitional Cell 7Breast Neoplasms 7Melanoma 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Esophageal Neoplasms 5Carcinosarcoma 5Carcinoma, Hepatocellular 5Vaginal Neoplasms 4Triple Negative Breast Neoplasms 4Thyroid Neoplasms 4Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Testicular Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Multiple Myeloma 3Cholangiocarcinoma 3Brain Neoplasms 3Vulvar Neoplasms 2

Interventions

Hysterectomy 2ipatasertib 1entinostat 1Telemedicine 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Ovariectomy 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Magnetic Resonance Spectroscopy 1Interviews as Topic 1Health Promotion 1Exercise Test 1Educational Status 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Magnetic Resonance Spectroscopy × Gynecologic × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡